ROCHE-OSI3364G

Study Sponsor : Roche

Study Title

A Phase III, Multi-Center, Open Label, Randomized Clinical Trial to Evaluate The Efficacy of Avastin (BEVACIZUMAB) in Combination with Tarceva (Erlotinib Hydrochloride) Compared with Tarceva Alone for Treatment of Recurrent or Refractory Stage IIIB/IV Non Small Cell Lung Cancer

Medicine or Vaccine (generic name)

erlotinib

Sponsor Identification Number

OSI3364G

Trial Registry Identification Number(#'s)

NCT00130728

Medical Condition

malignant neoplasm of bronchus and lung

Phase

Phase 3

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT00130728?term=OSI3364G&rank=1

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

January 2016